Table 1.
Clinicopathologic characteristics of patients with diffuse large B-cell lymphoma (DLBCL) with low or high levels of hnRNP K expression
| Characteristic | DLBCL |
GCB-DLBCL |
ABC-DLBCL |
||||||
|---|---|---|---|---|---|---|---|---|---|
| hnRNP Khigh | hnRNP Klow | P * | hnRNP Khigh | hnRNP Klow | P * | hnRNP Khigh | hnRNP Klow | P * | |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||||
| Age, y | |||||||||
| <60 | 15 (32.6) | 12 (41.4) | .47 | 7 (36.8) | 9 (56.3) | .32 | 8 (29.6) | 3 (23.1) | 1.0 |
| ≥60 | 31 (67.4) | 17 (58.6) | 12 (63.2) | 7 (43.8) | 19 (70.4) | 10 (76.9) | |||
| Sex | |||||||||
| Male | 25 (54.3) | 19 (65.5) | .47 | 11 (57.9) | 10 (62.5) | 1.0 | 14 (51.9) | 9 (69.2) | .33 |
| Female | 21 (45.7) | 10 (34.5) | 8 (42.1) | 6 (37.5) | 13 (48.1) | 4 (30.8) | |||
| Stage | |||||||||
| I–II | 16 (37.2) | 16 (55.2) | .15 | 12 (66.7) | 9 (56.3) | .73 | 4 (16.0) | 7 (53.8) | .02 |
| III–IV | 27 (62.7) | 13 (44.8) | 6 (33.3) | 7 (43.8) | 21 (84.0) | 6 (46.2) | |||
| B symptoms | |||||||||
| No | 25 (61.0) | 20 (74.1) | .31 | 13 (76.5) | 11 (73.3) | 1.0 | 12 (50.0) | 9 (75.0) | .28 |
| Yes | 16 (39.0) | 7 (25.9) | 4 (23.5) | 4 (26.7) | 12 (50.0) | 3 (25.0) | |||
| Serum LDH levels | |||||||||
| Normal | 17 (47.2) | 13 (52.0) | .80 | 8 (57.1) | 9 (64.3) | 1.0 | 9 (40.9) | 4 (36.4) | 1.0 |
| Elevated | 19 (52.8) | 12 (48.0) | 6 (42.9) | 5 (35.7) | 13 (59.1) | 7 (63.6) | |||
| No. of extranodal sites | |||||||||
| 0 or 1 | 34 (73.9) | 26 (89.7) | .14 | 14 (73.7) | 14 (87.5) | .42 | 20 (74.1) | 12 (92.3) | .24 |
| ≥2 | 12 (26.1) | 3 (10.3) | 5 (26.3) | 2 (12.5) | 7 (25.9) | 1 (7.7) | |||
| ECOG performance status | |||||||||
| 0 or 1 | 24 (66.7) | 22 (88.0) | .07 | 9 (64.3) | 13 (92.9) | .17 | 15 (68.2) | 9 (81.8) | .68 |
| ≥2 | 12 (33.3) | 3 (12.0) | 5 (35.7) | 1 (7.1) | 7 (31.8) | 2 (18.2) | |||
| Largest tumor size, cm | |||||||||
| <5 | 18 (52.9) | 10 (58.8) | .77 | 9 (60.0) | 6 (60.0) | 1.0 | 9 (47.4) | 4 (57.1) | 1.0 |
| ≥5 | 16 (47.1) | 7 (41.2) | 6 (40.0) | 4 (40.0) | 10 (52.6) | 3 (42.9) | |||
| IPI risk group | |||||||||
| 0–2 | 21 (50.0) | 22 (78.6) | .02 | 11 (64.7) | 12 (80.0) | .44 | 10 (40.0) | 10 (76.9) | .04 |
| 3–5 | 21 (50.0) | 6 (21.4) | 6 (35.3) | 3 (20.0) | 15 (60.0) | 3 (23.1) | |||
| Therapy response | |||||||||
| Complete response | 23 (50.0) | 26 (96.3) | <.001 | 12 (63.2) | 16 (100.0) | .009 | 11 (40.7) | 12 (92.3) | .002 |
| Noncomplete response | 23 (50.0) | 1 (3.7) | 7 (36.8) | 0 (0.0) | 16 (59.3) | 1 (7.7) | |||
*
Characteristics are compared by Fisher exact test. P values are two-sided. ABC = activated B-cell–like; ECOG = Eastern Cooperative Oncology Group; GCB = germinal center B-cell–like; hnRNP K = heterogeneous nuclear ribonucleoprotein K; LDH = lactate dehydrogenase; IPI = International Prognostic Index.